CareDx, Inc. vs AbCellera Biologics Inc.
CDNA wins the Tale of the Tape 7–1.
🏆 Tale of the Tape
Green = winner in each category. Higher is better except P/E (lower = cheaper).
Fundamentals
| Metric | CDNA | ABCL |
|---|---|---|
| Market Cap | $1.2B | — |
| P/E Ratio | — | — |
| Forward P/E | 20.1x | — |
| P/B | 3.73x | — |
| Dividend Yield | — | — |
| Beta | 2.49 | — |
Quantitative Metrics
| Metric | CDNA | ABCL |
|---|---|---|
| DCF Fair Value | $6.84 | — |
| DCF Upside | -59.4% | — |
| Piotroski F | 5/9 | 4/9 |
| Altman Z | 3.21 | — |
| Beneish M | -3.32 | — |
| FCF Yield | 4.55% | — |
| Net Debt/EBITDA | — | — |
| ROIC | -6.1% | -12.4% |
| WACC | 19.9% | — |
| ROIC – WACC | -26.0pp | — |
| Gross Margin | 67.5% | — |
| Net Margin | -5.6% | -194.9% |
| Rev Growth YoY | 13.8% | 160.6% |
| Sharpe (1Y) | 0.13 | — |
| Max Drawdown 3Y | -66.0% | — |
| FCF Payout Ratio | — | — |
CDNA Price
ABCL Price
ETF Exposure
More Comparisons
Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.
CDNA vs ABCL: Head-to-Head Analysis
CareDx, Inc. (CDNA) and AbCellera Biologics Inc. (ABCL) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, CDNA leads 7–1 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.
In terms of capital efficiency, CDNA generates a return on invested capital (ROIC) of -6.1% compared to ABCL's -12.4%. This suggests CDNA is more effective at deploying capital to generate shareholder returns.
CDNA appears in 3 ETFs tracked by SecuritiesDB, while ABCL appears in 2 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.
Frequently Asked Questions
Which stock is the better investment, CDNA or ABCL?
Our quantitative analysis compares CDNA and ABCL across nine fundamental dimensions. CDNA wins the Tale of the Tape 7–1. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.
Are CDNA and ABCL correlated?
Correlation data is not yet available for this pair. Check back after both stocks have sufficient trading history.
How is the Tale of the Tape scored?
The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.